Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Published:2018-06-12 Issue:9 Volume:20 Page:2210-2219
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ahrén Bo¹^ORCID,Atkin Stephen L.²^ORCID,Charpentier Guillaume³,Warren Mark L.⁴^ORCID,Wilding John P. H.⁵,Birch Sune⁶,Holst Anders Gaarsdal⁶,Leiter Lawrence A.⁷^ORCID

Affiliation:

1. Department of Clinical Sciences, Lund University; Lund Sweden

2. Weill Cornell Medical College Qatar; Doha Qatar

3. Department of Diabetes and Endocrinology, Centre Hospitalier Régional Gilles de Corbeil; Évry France

4. Endocrinology and Metabolism, Physicians East; Greenville North Carolina

5. Institute of Ageing and Chronic Disease, University of Liverpool; Liverpool UK

6. Novo Nordisk A/S; Søborg Denmark

7. Li Ka Shing Knowledge Institute; St. Michael's Hospital, University of Toronto; Toronto Canada

Funder

Novo Nordisk A/S

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13353/fullpdf

Reference43 articles.

1. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis;Guh;BMC Public Health,2009

2. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism;Poirier;Circulation,2006

3. Obesity as a disease;Jung;Br Med Bull,1997

4. Quality of life in relation to overweight and body fat distribution;Han;Am J Public Health,1998

5. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials;Franz;J Acad Nutr Diet,2015

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist;Gynecologic Oncology;2024-11

2. Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis;Cureus;2024-09-09

3. Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data;Journal of Diabetes Investigation;2024-09-07

4. Adherence to glucagon‐like peptide‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study;Diabetes, Obesity and Metabolism;2024-08-31

5. Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial;Diabetes, Obesity and Metabolism;2024-08-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3